Highlights Pacific Shuanglin Bio-pharmacy Co., LTD

Equities

000403

CNE000000F14

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
26.7 ^CNY	-0.34%		-2.23%	-1.98%

May. 23	Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin	MT
May. 22	Pacific Shuanglin Bio-pharmacy Co., LTD Approves Cash Dividend for the Year 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin	May. 23	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Cash Dividend for the Year 2023	May. 21	CI
Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License	May. 09	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Pacific Shuanglin Bio-pharmacy's 2023 Profit Jumps 4% Despite Lower Revenue; Shares Rise 4%	Apr. 15	MT
Pacific Shuanglin Bio-pharmacy's Profit Seen More Than Doubling in Q1; Shares Up 3%	Apr. 15	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Pacific Shuanglin Bio-pharmacy Unit Gets Nod to Trial Human Coagulation Factor IX	Nov. 06	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-18	CI
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Pacific Shuanglin Bio-pharmacy Obtains Blood Plasma Collection License	23-08-08	MT
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.	23-07-21	CI
Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback announced on September 1, 2022 has expired with 1,968,378 shares, representing 0.27% for CNY 40.1 million.	23-07-19	CI
Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces Final Dividend Implementation on A Shares for the Year 2022, Payable on July 20, 2023	23-07-14	CI
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.	23-07-03	CI
Pacific Shuanglin Bio-pharmacy's Unit Gets Permit to Operate Two Plasma Hubs	23-05-26	MT
Pacific Shuanglin Bio-Pharmacy Co., Ltd Approves 2022 Profit Distribution Plan	23-05-23	CI
Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) completed the acquisition of 20.99% stake in Pacific Shuanglin Bio-pharmacy Co., LTD from Hangzhou Zhemintou Tianhong Investment Partnership Enterprise (LP) and Zhejiang Private Enterprise United Investment Co., Ltd.	23-05-22	CI
Pacific Shuanglin Bio-pharmacy Signs Drug Supply, Distribution Deal With Brazil’s Hypera Pharma	23-05-05	MT
Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces Final Cash Dividend (Tax Included) for 2022	23-05-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pacific Shuanglin Bio-pharmacy Co., LTD

Equities

000403

CNE000000F14

Highlights

Filters